# Alterations of lipoprotein subfractions in GH-deficient adults

**Authors:** Balázs Ratku, Hajnalka Lőrincz, Sára Csiha, Lajos Bíró, Annamária Erdei, Eszter Berta, Dóra Ujvárosy, Miklós Bodor, Endre V. Nagy, Zoltán Szabó, Mariann Harangi, Sándor Somodi

PMC · DOI: 10.3389/fendo.2025.1696426 · Frontiers in Endocrinology · 2025-11-05

## TL;DR

This study finds that GH-deficient adults have altered lipoprotein subfractions, suggesting a more detailed analysis could improve cardiovascular risk assessment.

## Contribution

The study reveals novel associations between GH deficiency, IGF-1 levels, and specific lipoprotein subfractions, offering new insights into cardiovascular risk.

## Key findings

- GH-deficient patients showed altered lipoprotein subfractions despite normal standard lipid parameters.
- Higher S1P levels and altered HDL subfractions were observed in GH-deficient patients compared to controls.
- Log10IGF-1 was strongly correlated with HDL subfractions, indicating a novel link between GH and lipid metabolism.

## Abstract

Dyslipidemia is a common complication of adult growth hormone deficiency (AGHD) and considered an important contributor to increased mortality. Previous studies mainly focused on quantitative assessment of lipoproteins, but lipoprotein subfractions and their relationship with insulin-like growth factor 1 (IGF-1) have not been explored.

To perform a comprehensive evaluation of lipoprotein subfractions and measuring apolipoprotein L1 (apoL1), sphingosine 1-phosphate (S1P) and apolipoprotein M (apoM) in AGHD.

11 GH-substituted (GHS) patients, 9 GH-unsubstituted (GHU) patients and 37 controls were included in the study. Lipoprotein subfractions were separated by the Lipoprint system. ApoL1, apoM and S1P were determined by ELISA. In the GHS patients GH-replacement was discontinued for 2 months. Measurements were performed before GH-discontinuation, at the end of the 2-month GH-withdrawal, and 1 month after reinstituting GH-replacement.

Standard lipid parameters, apoM and apoL levels were not different between the groups. GHU patients demonstrated lower apolipoprotein A1 compared to controls (p=0.02) and higher apolipoprotein B100 compared to GHS (p=0.02). GHU and GHS showed higher S1P levels compared to controls (p=0.04 and p=0.01, respectively). Both GHU and GHS patients also presented higher percentage of intermediate-density lipoprotein (IDL) compared to controls (p=0.03 and p=0.01, respectively). Mean LDL size was lower in GHU compared to GHS (p=0.04). Percentage of intermediate HDL was lower in GHU and GHS compared to controls (p<0.001 and p<0.01, respectively). GHU demonstrated higher percentage of small HDL than controls (p<0.001). Overall, log10IGF-1 correlated positively with the percentage of large HDL (r=0.27; p=0.04) and intermediate HDL (r=0.38; p<0.01) and negatively with the percentage of small HDL (r=-0.46; p<0.01). Log10IGF-1 was the best predictor of small HDL (standardized β=-0.46; p<0.001) in overall subjects. In the GH-withdrawal study, the amount of HDL-6 increased with GH-withdrawal (p=0.03) and the percentage of IDL increased with reinstitution (p=0.05).

Despite no changes in standard lipid parameters, considerable alterations of lipoprotein subfractions were revealed in GH-deficient adults indicating that lipoprotein subfraction analysis may allow for a more precise cardiovascular risk assessment in AGHD. Associations between HDL subfractions and Log10IGF-1 demonstrate a novel insight into the role of GH in lipid metabolism.

## Linked entities

- **Proteins:** IGF1 (insulin like growth factor 1), APOL1 (apolipoprotein L1), APOM (apolipoprotein M), MBTPS1 (membrane bound transcription factor peptidase, site 1)
- **Diseases:** dyslipidemia (MONDO:0002525)

## Full-text entities

- **Genes:** APOB (apolipoprotein B) [NCBI Gene 338] {aka FCHL2, FLDB, LDLCQ4, apoB-100, apoB-48}, APOA1 (apolipoprotein A1) [NCBI Gene 335] {aka AMYLD3, HPALP2, apo(a)}, APOM (apolipoprotein M) [NCBI Gene 55937] {aka G3a, HSPC336, NG20, apo-M}, GGH (gamma-glutamyl hydrolase) [NCBI Gene 8836] {aka GATD10, GH}, APOL1 (apolipoprotein L1) [NCBI Gene 8542] {aka APO-L, APOL, APOL-I, FSGS4}, IGF1 (insulin like growth factor 1) [NCBI Gene 3479] {aka IGF, IGF-I, IGFI, MGF}
- **Diseases:** growth hormone deficiency (MESH:D004393), GH (MESH:D006432), AGHD (MESH:C537404), Dyslipidemia (MESH:D050171)
- **Chemicals:** lipid (MESH:D008055), S1P (MESH:C060506), GH (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12626791/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12626791/full.md

## References

69 references — full list in the complete paper: https://tomesphere.com/paper/PMC12626791/full.md

---
Source: https://tomesphere.com/paper/PMC12626791